Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic efficacy of dendritic cell vaccination in a novel syngeneic mouse model of diffuse hemispheric glioma, H3 G34-mutant.

Journal of neuro-oncology - 2 Apr 2026

Owens Geoffrey C, Contreras Erick M, Kienzler Jenny C, Treger Janet, Soto Horacio, Orpilla Joey R, Qiao Chloe, Chang Julia W, Lee Alexander, Kim Wi-Jin, Sun Matthew Z, Peeters Sophie F, Bethel Jacob A, Kondajji Aditya M, Holland Eric C, Becher Oren J, Liau Linda M, Prins Robert M, Wang Anthony C

Abstract excerpt

PURPOSE: The prognosis for pediatric high-grade gliomas associated with mutations in the H3-3A gene is very poor. To investigate whether tumor lysate-pulsed dendritic cells (DC) together with checkpoint blockade might be a potential treatment modality for diffuse hemispheric glioma H3 G34-mutant (DHG), we have developed a novel syngeneic mouse model. METHODS: We used the RCAS/tv-A system to target the expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Dendritic Cells

Share to Glioma

Share to Immunotherapy

Share to Mice, Inbred C57BL

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 41925941
DOI: 10.1007/s11060-026-05545-z
PMCID: PMC13046641

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic efficacy of dendritic cell vaccination in a novel syngeneic mouse model of diffuse hemispheric glioma, H3 G34-mutant.PMID 41925941Read ↗

H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Diffuse Hemispheric GliomasSemantic proximity Read ↗

A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of H3K27M.Semantic proximity Read ↗

A road map for the treatment of pediatric diffuse midline glioma.Semantic proximity Read ↗

A New Mouse Model of Diffuse Midline Glioma to Test Targeted ImmunotherapiesSemantic proximity Read ↗

H3K27M Mutation Reshapes the Antigenic Landscape in Diffuse Midline GliomaSemantic proximity Read ↗

Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function.Semantic proximity Read ↗

H3.3 G34R-engineered murine glioma reproduces diffuse perineuronal infiltration of diffuse hemispheric glioma, H3 G34-mutant.Semantic proximity Read ↗

In vivo mouse models for adult brain tumors: Exploring tumorigenesis and advancing immunotherapy developmentSemantic proximity Read ↗

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomasSemantic proximity Read ↗

STINGing the immune system: lessons learned through a model of G34-mutant pediatric high-grade glioma.Semantic proximity Read ↗

<i>De novo</i> H3.3K27M-altered Diffuse Midline Glioma in human brainstem organoids to dissect GD2 CAR T cell functionSemantic proximity Read ↗

H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.